Surgical Outcomes, Ocular Safety and Tolerability of Bio-Interventional Cyclodialysis with Allograft Scleral Reinforcement: Clinical Experience of More than 240 Cases
Journal of Clinical Medicine · 06.08.2024 · 13 (16) · 4593
DOI: 10.3390/jcm13164593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.08.2024. Verfasst von Craig J Chaya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah, Salt Lake City, UT 84112, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research to Prevent Blindness, New York, NY.
Abstract (Originalsprache)
Background
To report the surgical safety of reinforced bio-interventional cyclodialysis with scleral allograft reinforcement.
Methods
This was a consecutive case series of 243 eyes with open-angle glaucoma who underwent a bio-scaffolded cyclodialysis (BSC) procedure for uveoscleral outflow enhancement using allogeneic bio-spacers to maintain patency of the internal filtration conduit.
Results
79% of the eyes underwent concomitant phacoemulsification cataract surgery prior to BSC intervention, while the remaining eyes underwent stand-alone BSC surgery. All patients had a postoperative surgical safety period of at least 30 days. There were no sight-threatening or serious ocular adverse events. There was one case of prolonged iritis beyond 30 days, which resolved with topical treatment. Two cases (0.8%) of intraoperative and five (2%) of postoperative non-sight-threatening hyphema were without clinical sequelae, which resolved with conservative management. There were 11 cases of IOP elevation and one case of numeric hypotony without maculopathy, which resolved within the study period. The rate of secondary surgical intervention for IOP control was low, and overall, IOP for the cohort improved in the postoperative period, with 78.6% of eyes achieving IOP ≤ 18 mmHg without an increase in medications.
Conclusions
Allogeneic biotissue for cyclodialysis intervention demonstrates a biocompatible ocular profile as an implantable material for internal scleral reinforcement during uveoscleral outflow enhancement surgery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, Moran Eye Center, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Ophthalmology, Duke Eye Center, Duke University, Durham, NC 27708, USA.
- Department of Ophthalmology, New York Eye and Ear of Mount Sinai, New York, NY 10003, USA.
- Visionary Eye Institute, Newport Beach, CA 92663, USA.
- Coastal Research Associates, Atlanta, GA 30076, USA.
ORCID-Profile: Craig J Chaya, Leon W Herndon, Tsontcho Ianchulev
Förderung
- Research to Prevent Blindness, New York, NY
Zitieren
APA
Chaya, C. J., Herndon, L. W., Lince, J., Radcliffe, N., Sadri, E., Yadgarov, A., & Ianchulev, T. (2024). Surgical Outcomes, Ocular Safety and Tolerability of Bio-Interventional Cyclodialysis with Allograft Scleral Reinforcement: Clinical Experience of More than 240 Cases. Journal of Clinical Medicine, 13(16), 4593. https://doi.org/10.3390/jcm13164593
Vancouver
Chaya CJ, Herndon LW, Lince J, Radcliffe N, Sadri E, Yadgarov A, et al. Surgical Outcomes, Ocular Safety and Tolerability of Bio-Interventional Cyclodialysis with Allograft Scleral Reinforcement: Clinical Experience of More than 240 Cases. Journal of Clinical Medicine. 2024;13(16):4593. doi:10.3390/jcm13164593
BibTeX
@article{Chaya2024,
author = {Chaya, Craig J and Herndon, Leon W and Lince, Jorge and Radcliffe, Nathan and Sadri, Ehsan and Yadgarov, Arkadiy and Ianchulev, Tsontcho},
title = {Surgical Outcomes, Ocular Safety and Tolerability of Bio-Interventional Cyclodialysis with Allograft Scleral Reinforcement: Clinical Experience of More than 240 Cases},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {16},
pages = {4593},
doi = {10.3390/jcm13164593}
}
EUVIMED